Torrent Pharmaceuticals reported a 51% surge in consolidated revenue to Rs 4,979 crore for Q2 FY27, largely driven by its merger with J.B. Chemicals & Pharmaceuticals. Despite strong operational growth and a 54% jump in EBITDA, net profit declined 9.6% to Rs 534 crore, reflecting transitional integration costs. Management expects these challenges to be temporary, but investors remain focused on how quickly the combined entity can stabilize margins.
Torrent Pharmaceuticals Q2 Profit Dips 10% Post-Merger
Revenue grew by 51% YoY to Rs 4,979 crore, while Net Profit fell 9.6% to Rs 534 crore.
Reader Takeaway: Strong topline growth follows JBCPL merger, but temporary integration hurdles are currently weighing on net profitability.
What just happened
Torrent Pharmaceuticals has released its Q2 FY27 financial results, marking the first full quarter reflecting the consolidation of J.B. Chemicals & Pharmaceuticals Limited (JBCPL). The merger, which became effective on July 8, 2026, has fundamentally altered the company's scale, resulting in a significant 51% YoY revenue jump to Rs 4,979 crore. Operating EBITDA rose 54% to Rs 1,666 crore, with margins holding steady at 33.5%.
Why this matters
While top-line growth is substantial, bottom-line performance dipped by nearly 10% compared to the same period last year. Management attributed this pressure to a "transient impact" resulting from the post-merger integration process. This includes the realignment of manufacturing systems, quality management, and global business networks. Investors are looking for signs of operational efficiency as these one-time integration activities subside.
Business Performance
The India base business showed resilience, growing by 20% to Rs 2,181 crore. Meanwhile, the international business—combining the base and JBCPL operations—reported Rs 1,991 crore in revenue, a 48% increase. The scaling of operations is evident in the EBITDA figures, though the bottom line reflects the inevitable friction of integrating two large-scale pharmaceutical entities.
Risks to watch
The primary risk for shareholders is the duration of the integration phase. Management has described the current revenue headwinds as transient, but any prolonged impact on margins or sustained operational friction could weigh on stock sentiment in the near term.
What to track next
Watch for the upcoming quarters to see if the net profit trajectory aligns with the robust revenue growth. Specifically, look for reduced integration-related expenses and consistent margin improvements across the merged entity.